Germany’s cost-of-care debate is moving from rhetoric to legislation. And it is landing hard on medicines and hospitals. The latest discussions on German drug price reforms come as Berlin is trying to stabilise statutory health insurance funds that are projected to drift deeper into deficit. Government estimates put the potential shortfall at around €40bn by 2030 if spending is not reined in.
Germany already spends more than €500bn a year on healthcare. That makes it Europe’s biggest bill payer by some distance, and it is now pushing payers and politicians towards tougher choices.
Chancellor Friedrich Merz has framed the coalition’s package as “historic”. The bill is moving through Parliament with an eye on final approval before the summer recess. Opposition parties have attacked the package as unfair to workers. Others say it still fails to go far enough.
German Drug Price Reforms Target a €40bn Gap
The proposed changes would lean heavily on pharmaceuticals. The centrepiece is a higher mandatory rebate on medicines, rising to about 10.5% from 2027, with scope to ratchet higher if insurer finances worsen.
The bill would also give insurers more room to cluster similar patented medicines and steer prescribing towards cheaper options within the same therapeutic area. That would increase competition among branded drugs, not just between brands and generics.
Industry leaders warn that this risks turning Germany into a tougher launch market. The German pharma lobby has argued the measures could weaken the country’s attractiveness for investment and ultimately limit access to cutting-edge treatments.
German Drug Price Reforms Raise Launch Risks As US Pressure Grows
Germany’s move is landing as US pricing politics heat up. President Donald Trump has signalled support for aligning US drug prices with lower prices paid abroad, including in Europe. That creates a global pricing trap for manufacturers. If a low European price becomes a reference point for the US, the hit to margins can be severe.
There are already early examples of caution about launches. Reuters has reported that companies are delaying or reconsidering European introductions as uncertainty grows. Denmark has also become a flashpoint, after Amgen withdrew its cholesterol drug Repatha from the Danish market, citing changed market dynamics, with local commentary linking the move to “most favoured nation” pricing pressure.
For European policymakers, the risk is gradual but real. Economists warn that investment decisions shift quietly at first. By the time reduced R&D footprints or slower launches are obvious, they can be hard to reverse. That matters as China accelerates its push into innovative medicines, intensifying competition for capital and talent.
Hospitals Face Cuts Without A Full Redesign
Drug pricing is not the only battleground. Hospitals, one of the biggest cost drivers, are also being asked to absorb tighter reimbursement. Germany still runs a high number of clinics compared with peers, and inpatient stays remain relatively long.
Market nerves are showing. Fresenius, Germany’s largest private hospital operator, has seen its shares fall sharply since February amid uncertainty over reform signals and earnings impact. Larger groups may ultimately benefit if weaker standalone hospitals close, but executives argue that the package does not fully address structural inefficiencies.
Read the Original Article (May require a subscription)